Neither treatment is a cure. Drugs that target and clear amyloid plaque can also have significant safety risks, including swelling and bleeding in the brain that can be severe and even fatal in some cases.
Three patients who took Eli Lilly’s drug in a late-stage trial died from severe forms of those side effects, called amyloid-related imaging abnormalities, or ARIA.